Categories: Bloodborne pathogens, Cancer, Chemicals, Construction, Health care, Personal protective equipment, Stress, Transportation, Violence, women
May 13th, 2013 10:04 am ET -
Naomi Swanson,Ph.D.; Julie Tisdale-Pardi, MA; CAPT Leslie MacDonald, Sc.D.; Hope M. Tiesman, Ph.D.
This week is Women’s Health Week. With over 58% of U.S. women in the labor force[i], the workplace must be considered when looking at women’s overall health. We must keep in mind that susceptibility to hazards can be different for men and women. Additionally, women face different workplace health challenges than men partly because men and women tend to have different kinds of jobs. Women generally have more work-related cases of carpal tunnel syndrome, tendonitis, respiratory diseases, infectious diseases, and anxiety and stress disorders. Social, economic, and cultural factors also put women at risk for injury and illness. While workplace exposures can affect both male and female reproduction, issues related to reproduction and pregnancy are of particular concern to women. Below you will find summaries, with links to more research, of some hazards faced by women in the workplace as well as links to industry-specific research from NIOSH that relates to women. More information is available on the NIOSH topic page Women’s Safety and Health Issues at Work.
3 Comments -
Read more
Categories: Cancer, Manufacturing, Nanotechnology
March 11th, 2013 2:00 pm ET -
Vincent Castranova, PhD; Charles L Geraci, PhD; Paul Schulte, PhD

Alveolar Bronchiolar Carcinoma of the Lung with Metastases in a Blood Vessel (arrow). Photo courtesy of Linda Sargent, Ph.D., NIOSH
Earlier today, at the annual meeting of the Society of Toxicology, NIOSH researchers reported preliminary findings from a new laboratory study in which mice were exposed by inhalation to multi-walled carbon nanotubes (MWCNT). The study was designed to investigate whether these tiny particles have potential to initiate or promote cancer. By “initiate,” we mean the ability of a substance to cause mutations in DNA that can lead to tumors. By “promote,” we mean the ability of a substance to cause cells that have already sustained such DNA mutations to then become tumors.
It is very important to have new data that describe the potential health hazards that these materials might represent, so that protective measures can be developed to ensure the safe advancement of nanotechnology in the many industries where it is being applied.
6 Comments -
Read more
Categories: Cancer, Manufacturing, Respiratory health, Technology
August 29th, 2012 10:58 am ET -
Simone Tramma, MD, MS; Eileen Storey, MD, MPH; David Weissman, MD
Last year we posted two blogs on the use of computerized tomography (CT) scans of the chest for lung cancer screening — Helical CT Scans and Lung Cancer Screening1 and Low-dose CT Scans and Lung Cancer Screening in the Occupational Setting.2 Since the postings, various organizations have provided guidance with differing implications for early detection of lung cancer in workers who have been exposed to lung carcinogens in the occupational setting. This blog provides an update on scientific investigation and the various recommendations that have been made in this area.
2 Comments -
Read more
Categories: Cancer, Manufacturing, Respiratory health, Technology
August 4th, 2011 2:50 pm ET -
Simone Tramma, MD, MS; Eileen Storey, MD, MPH; Douglas B. Trout, MD, MHS; Marie Haring Sweeney, PhD, MPH
In early 2011 NIOSH posted a blog entry commenting on the preliminary results from the National Lung Screening Trial (NLST), funded by the National Cancer Institute, that found a 20.3% reduction in deaths from lung cancer among current or former heavy smokers who were screened with low-dose helical computed tomography (CT) versus those screened by chest X-ray (CXR). On June 29, 2011, the peer-reviewed primary results from the NLST were published online in the New England Journal of Medicine. This is an update to the previous blog.1
The National Lung Screening Trial
The National Lung Screening Trial (NLST)2 was a national randomized controlled trial launched by the National Cancer Institute (NCI) in 2002 to determine whether annual screening with low-dose helical CT would lead to earlier detection and reduced mortality from lung cancer relative to screening with CXR.
6 Comments -
Read more